Fisher Asset Management LLC Has $2.37 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Fisher Asset Management LLC grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 941.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 122,260 shares of the biotechnology company’s stock after buying an additional 110,516 shares during the period. Fisher Asset Management LLC owned approximately 0.10% of Arrowhead Pharmaceuticals worth $2,368,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in Arrowhead Pharmaceuticals by 17.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 71,136 shares of the biotechnology company’s stock worth $2,035,000 after purchasing an additional 10,568 shares during the period. Janus Henderson Group PLC raised its holdings in Arrowhead Pharmaceuticals by 21.3% in the 1st quarter. Janus Henderson Group PLC now owns 57,449 shares of the biotechnology company’s stock worth $1,641,000 after acquiring an additional 10,082 shares during the period. California State Teachers Retirement System grew its holdings in Arrowhead Pharmaceuticals by 14.1% in the 1st quarter. California State Teachers Retirement System now owns 122,486 shares of the biotechnology company’s stock valued at $3,503,000 after buying an additional 15,136 shares during the last quarter. Comerica Bank grew its stake in shares of Arrowhead Pharmaceuticals by 11.2% in the first quarter. Comerica Bank now owns 48,312 shares of the biotechnology company’s stock worth $1,382,000 after acquiring an additional 4,855 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Arrowhead Pharmaceuticals during the first quarter worth $269,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $26.03 on Friday. The stock has a market capitalization of $3.24 billion, a P/E ratio of -5.19 and a beta of 0.93. The company has a current ratio of 6.74, a quick ratio of 4.65 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $17.05 and a 1 year high of $39.83. The firm has a 50 day moving average of $20.05 and a 200-day moving average of $23.20.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. B. Riley reaffirmed a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Piper Sandler lowered their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, November 20th. Finally, Sanford C. Bernstein decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.70.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.